Henry Schein Inc

Align Technology was trading at its 52-week high of $398.88 on September 25. The stock reported its 52-week low of $180.31 on September 28, 2017.

Align Technology (ALGN) stock hasn’t received any recommendation updates since the stock was upgraded by several analysts in July.

In this series, we’ll analyze major spin-offs in the healthcare sector by Perrigo (PRGO), Eli Lilly (LLY), Danaher (DHR), and Henry Schein.

On April 23, Henry Schein (HSIC) announced its plans to spin off and merge its animal health business with Vets First Choice to form a joint venture, Vets First Corp.

Dentsply Sirona (XRAY) has delivered lower merger synergies than the company had estimated. It also took an impairment charge during 4Q17.

In 4Q17, Align Technology reported a sequential decline in its shipments of non-Invisalign SDC aligners to SDC.

Align Technology (ALGN) has been growing at a fast pace while it executes its strategic priorities around the world.

Increases in Align Technology’s (ALGN) Invisalign volumes and ASP were the major factors driving the company’s sales growth.

Of the 12 investment research firms following ALGN stock, ten of them have given the stock “buy” or “strong buy” recommendations.

In 3Q17, Align Technology trained nearly 1,000 doctors in China.

On October 6, 2017, Intuitive Surgical will start trading on a split-adjusted basis. It has scheduled a stock split for its shares in a ratio of 3:1.

Henry Schein reported 3Q15 net sales of $2,685.8 million, a rise of 2.4% compared to the net sales of $2,623.7 million in fiscal 3Q14.

The respective PE ratios of Patterson Companies and peers Henry Schein, DENTSPLY International, and VCA are 23.6x, 27.1x, 31.5x, and 25.9x as of November 24.